Zynerba Pharmaceuticals Company Profile (NASDAQ:ZYNE)

About Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Zynerba Pharmaceuticals logoZynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ZYNE
  • CUSIP: N/A
  • Web: www.zynerba.com
Capitalization:
  • Market Cap: $251.73 million
  • Outstanding Shares: 13,249,000
Average Prices:
  • 50 Day Moving Avg: $21.00
  • 200 Day Moving Avg: $18.70
  • 52 Week Range: $6.31 - $25.95
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.96
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $5.88 per share
  • Price / Book: 3.23
Profitability:
  • EBIDTA: ($26,590,000.00)
  • Return on Equity: -63.78%
  • Return on Assets: -56.66%
Debt:
  • Current Ratio: 7.19%
  • Quick Ratio: 7.19%
Misc:
  • Average Volume: 399,738 shs.
  • Beta: 4.87
  • Short Ratio: 3.69
 

Frequently Asked Questions for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) posted its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.55) by $0.05. View Zynerba Pharmaceuticals' Earnings History.

Where is Zynerba Pharmaceuticals' stock going? Where will Zynerba Pharmaceuticals' stock price be in 2017?

8 analysts have issued 12-month target prices for Zynerba Pharmaceuticals' stock. Their predictions range from $28.00 to $42.00. On average, they expect Zynerba Pharmaceuticals' share price to reach $32.25 in the next twelve months. View Analyst Ratings for Zynerba Pharmaceuticals.

What are analysts saying about Zynerba Pharmaceuticals stock?

Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (3/29/2017)
  • 2. Maxim Group analysts commented, "Cannabis-based therapies are starting to gain acceptance in the medical community with novel therapeutics in advanced clinical development." (2/23/2017)

Who are some of Zynerba Pharmaceuticals' key competitors?

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Who owns Zynerba Pharmaceuticals stock?

Zynerba Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Marshall Wace North America L.P. (3.54%), Vanguard Group Inc. (3.22%), Perceptive Advisors LLC (1.90%), Sphera Funds Management LTD. (0.76%), Granite Point Capital Management L.P. (0.75%) and MARSHALL WACE ASIA Ltd (0.62%). Company insiders that own Zynerba Pharmaceuticals stock include Armando Anido, James E Fickenscher, Michael Rapp and Suzanne M Hanlon. View Institutional Ownership Trends for Zynerba Pharmaceuticals.

Who sold Zynerba Pharmaceuticals stock? Who is selling Zynerba Pharmaceuticals stock?

Zynerba Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC. View Insider Buying and Selling for Zynerba Pharmaceuticals.

Who bought Zynerba Pharmaceuticals stock? Who is buying Zynerba Pharmaceuticals stock?

Zynerba Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Vanguard Group Inc., Sphera Funds Management LTD., Granite Point Capital Management L.P., MARSHALL WACE ASIA Ltd, Chartwell Investment Partners LLC, Iguana Healthcare Management LLC and Bluestein R H & Co.. Company insiders that have bought Zynerba Pharmaceuticals stock in the last two years include Armando Anido, James E Fickenscher and Michael Rapp. View Insider Buying and Selling for Zynerba Pharmaceuticals.

How do I buy Zynerba Pharmaceuticals stock?

Shares of Zynerba Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Zynerba Pharmaceuticals stock cost?

One share of Zynerba Pharmaceuticals stock can currently be purchased for approximately $19.00.

Analyst Ratings

Consensus Ratings for Zynerba Pharmaceuticals (NASDAQ:ZYNE) (?)
Ratings Breakdown: 8 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.25 (69.74% upside)

Analysts' Ratings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Jefferies Group LLCReiterated RatingBuy$32.00HighView Rating Details
5/13/2017Canaccord GenuitySet Price TargetBuy$35.00LowView Rating Details
5/13/2017Roth CapitalSet Price TargetBuy$30.00LowView Rating Details
5/9/2017Cantor FitzgeraldReiterated RatingBuy$28.00HighView Rating Details
4/1/2017Oppenheimer Holdings Inc.Set Price TargetBuy$29.00LowView Rating Details
3/28/2017HC WainwrightReiterated RatingBuy -> Buy$22.00 -> $30.00HighView Rating Details
3/13/2017Maxim GroupReiterated RatingBuy$32.00MediumView Rating Details
12/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$42.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Earnings by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Earnings History by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.55)($0.60)$0.07 millionViewN/AView Earnings Details
3/27/2017Q4 2016($0.75)($0.71)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.69)($0.67)$0.20 millionViewN/AView Earnings Details
8/11/2016Q2($0.53)($0.70)$0.03 millionViewN/AView Earnings Details
5/12/2016Q1($0.56)($0.49)$0.03 million$0.01 millionViewN/AView Earnings Details
3/14/2016Q415($0.29)($0.62)$0.20 million$0.05 millionViewN/AView Earnings Details
11/11/2015Q3($0.41)($0.44)$0.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
2017 EPS Consensus Estimate: ($2.25)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.62)($0.50)($0.56)
Q2 20173($0.62)($0.51)($0.57)
Q3 20173($0.64)($0.42)($0.55)
Q4 20173($0.66)($0.48)($0.58)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Insider Ownership Percentage: 10.02%
Institutional Ownership Percentage: 15.00%
Insider Trades by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Institutional Ownership by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Insider Trades by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Armando AnidoChairmanBuy5,000$19.70$98,500.00View SEC Filing  
5/12/2017James E FickenscherCFOBuy5,200$19.82$103,064.00View SEC Filing  
12/29/2016Michael RappMajor ShareholderBuy10,000$15.85$158,500.00View SEC Filing  
12/7/2016James E FickenscherCFOBuy7,000$14.08$98,560.00View SEC Filing  
8/16/2016Suzanne M HanlonInsiderSell3,000$10.53$31,590.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Latest Headlines for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Source:
DateHeadline
americanbankingnews.com logoZynerba Pharmaceuticals' (ZYNE) "Buy" Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - May 27 at 12:44 PM
americanbankingnews.com logoZynerba Pharmaceuticals Inc (ZYNE) CFO Purchases $103,064.00 in Stock
www.americanbankingnews.com - May 16 at 10:27 AM
americanbankingnews.com logoZynerba Pharmaceuticals Inc (ZYNE) Chairman Buys $98,500.00 in Stock
www.americanbankingnews.com - May 16 at 10:26 AM
americanbankingnews.com logoCantor Fitzgerald Comments on Zynerba Pharmaceuticals Inc's FY2017 Earnings (ZYNE)
www.americanbankingnews.com - May 15 at 8:18 AM
americanbankingnews.com logoZynerba Pharmaceuticals Inc (ZYNE) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 12 at 2:38 PM
americanbankingnews.com logoZynerba Pharmaceuticals Inc (ZYNE) to Post Q2 2017 Earnings of ($0.57) Per Share, Oppenheimer Holdings Forecasts
www.americanbankingnews.com - May 12 at 7:48 AM
americanbankingnews.com logoJefferies Group Brokers Reduce Earnings Estimates for Zynerba Pharmaceuticals Inc (ZYNE)
www.americanbankingnews.com - May 11 at 7:34 AM
finance.yahoo.com logoZynerba reports 1Q loss
finance.yahoo.com - May 11 at 4:23 AM
americanbankingnews.com logoZynerba Pharmaceuticals Inc (ZYNE) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - May 10 at 3:32 PM
globenewswire.com logoZynerba Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Highlights
globenewswire.com - May 10 at 8:44 AM
americanbankingnews.com logoCantor Fitzgerald Analysts Give Zynerba Pharmaceuticals Inc (ZYNE) a $28.00 Price Target
www.americanbankingnews.com - May 9 at 11:36 PM
feeds.benzinga.com logoCatalysts Growing Like Weeds For Zynerba Next Quarter
feeds.benzinga.com - May 9 at 3:52 PM
reuters.com logoBRIEF-Zynerba Pharmaceuticals reports Q1 loss per share $0.60 - Reuters
www.reuters.com - May 9 at 8:15 AM
nasdaq.com logoZynerba Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Highlights - Nasdaq
www.nasdaq.com - May 9 at 8:15 AM
finance.yahoo.com logoZynerba Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Highlights
finance.yahoo.com - May 9 at 8:15 AM
seekingalpha.com logoZynerba Pharmaceuticals' Development In The High-Growth Cannabinoid Space
seekingalpha.com - May 8 at 9:15 PM
finance.yahoo.com logoETFs with exposure to Zynerba Pharmaceuticals, Inc. : May 8, 2017
finance.yahoo.com - May 8 at 9:15 PM
americanbankingnews.com logoZynerba Pharmaceuticals Inc (ZYNE) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 8 at 9:00 AM
americanbankingnews.com logoZynerba Pharmaceuticals (ZYNE) Earning Somewhat Critical Media Coverage, Study Finds
www.americanbankingnews.com - May 1 at 3:50 PM
americanbankingnews.com logoZynerba Pharmaceuticals Inc (ZYNE) Expected to Announce Quarterly Sales of $240,000.00
www.americanbankingnews.com - April 30 at 9:32 AM
americanbankingnews.com logoZynerba Pharmaceuticals Inc (ZYNE) Expected to Post Earnings of -$0.55 Per Share
www.americanbankingnews.com - April 28 at 11:41 AM
finance.yahoo.com logoETFs with exposure to Zynerba Pharmaceuticals, Inc. : April 27, 2017
finance.yahoo.com - April 28 at 3:08 AM
americanbankingnews.com logoZynerba Pharmaceuticals (ZYNE) Given Media Sentiment Rating of 0.14
www.americanbankingnews.com - April 27 at 8:28 AM
americanbankingnews.com logoZynerba Pharmaceuticals (ZYNE) Earns News Sentiment Rating of 0.56
www.americanbankingnews.com - April 24 at 9:49 AM
investopedia.com logoThree Hot Junior Biotech Plays (CNAT, ZYNE)
www.investopedia.com - April 21 at 10:34 PM
americanbankingnews.com logoZynerba Pharmaceuticals (ZYNE) Receives Media Impact Score of 0.27
www.americanbankingnews.com - April 21 at 9:37 AM
americanbankingnews.com logoZynerba Pharmaceuticals (ZYNE) Earning Favorable Press Coverage, Analysis Shows
www.americanbankingnews.com - April 18 at 12:38 PM
finance.yahoo.com logoETFs with exposure to Zynerba Pharmaceuticals, Inc. : April 17, 2017
finance.yahoo.com - April 17 at 7:31 PM
americanbankingnews.com logoZynerba Pharmaceuticals Inc (ZYNE) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 17 at 3:24 PM
americanbankingnews.com logoZynerba Pharmaceuticals (ZYNE) Getting Somewhat Negative Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 15 at 7:46 AM
finance.yahoo.com logoImplied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options - Yahoo Finance
finance.yahoo.com - April 13 at 3:21 PM
nasdaq.com logoImplied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options - Nasdaq
www.nasdaq.com - April 13 at 8:00 AM
finance.yahoo.com logoImplied Volatility Surging for Zynerba Pharmaceuticals (ZYNE) Stock Options
finance.yahoo.com - April 13 at 8:00 AM
prnewswire.com logoHow These Generic Drugs Stocks are Faring? -- Zynerba Pharma, Patheon, SCYNEXIS, and Flexion Therapeutics - PR Newswire (press release)
www.prnewswire.com - April 11 at 8:17 AM
americanbankingnews.com logoZacks: Analysts Expect Zynerba Pharmaceuticals Inc (ZYNE) to Announce -$0.55 EPS
www.americanbankingnews.com - April 7 at 7:21 PM
marketwatch.com logoWorld's First Marijuana ETF Launched
www.marketwatch.com - April 7 at 6:42 PM
investorplace.com logoBest Stocks for 2017: Zynerba Pharmaceuticals Inc (ZYNE) Stock Dominates in Q1 - Investorplace.com
investorplace.com - April 7 at 1:41 PM
investorplace.com logoBest Stocks for 2017: Zynerba Pharmaceuticals Inc (ZYNE) Stock Dominates in Q1
investorplace.com - April 6 at 1:12 PM
americanbankingnews.com logoZynerba Pharmaceuticals Inc (ZYNE) Short Interest Down 14.3% in March
www.americanbankingnews.com - April 5 at 7:34 AM
americanbankingnews.com logoBrokers Offer Predictions for Zynerba Pharmaceuticals Inc's FY2021 Earnings (ZYNE)
www.americanbankingnews.com - April 3 at 12:55 PM
americanbankingnews.com logoZynerba Pharmaceuticals Inc (ZYNE) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - April 3 at 12:26 PM
americanbankingnews.com logoZynerba Pharmaceuticals Inc (ZYNE) PT Set at $29.00 by Oppenheimer Holdings Inc.
www.americanbankingnews.com - April 2 at 11:31 PM
finance.yahoo.com logoZYNERBA PHARMACEUTICALS, INC. Financials
finance.yahoo.com - April 1 at 12:25 PM
prnewswire.com logoPain-Reducing Combination Therapies Proving Successful Thanks to Innovative, Specialty Pharma Players
www.prnewswire.com - March 30 at 3:41 PM
americanbankingnews.com logoQ1 2017 Earnings Estimate for Zynerba Pharmaceuticals Inc (ZYNE) Issued By Roth Capital
www.americanbankingnews.com - March 30 at 8:47 AM
americanbankingnews.com logoFY2017 Earnings Forecast for Zynerba Pharmaceuticals Inc (ZYNE) Issued By Jefferies Group
www.americanbankingnews.com - March 29 at 11:56 AM
americanbankingnews.com logoZynerba Pharmaceuticals Inc (ZYNE) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 10:19 AM
americanbankingnews.com logoMaxim Group Reiterates "Buy" Rating for Zynerba Pharmaceuticals Inc (ZYNE)
www.americanbankingnews.com - March 28 at 10:44 AM
americanbankingnews.com logoBrokers Issue Forecasts for Zynerba Pharmaceuticals Inc's Q1 2017 Earnings (ZYNE)
www.americanbankingnews.com - March 28 at 8:49 AM
reuters.com logoBRIEF-Zynerba Pharmaceuticals qtrly loss per share $0.71
www.reuters.com - March 27 at 8:08 PM

Social

Chart

Zynerba Pharmaceuticals (ZYNE) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff